Allianz Asset Management Gmb H Assembly Biosciences, Inc. Transaction History

Allianz Asset Management Gmb H

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$4.87 - $17.29 $93,455 - $331,795	-19,190 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$15.08 - $27.04 $213,487 - $382,805	-14,157 Reduced 42.45%	19,190 $315,000
Q2 2020 Aug 14, 2020	BUY	$14.57 - $23.96 $79,450 - $130,653	5,453 Added 19.55%	33,347 $778,000
Q1 2020 May 14, 2020	SELL	$10.27 - $21.23 $346,992 - $717,298	-33,787 Reduced 54.78%	27,894 $414,000
Q4 2019 Feb 13, 2020	BUY	$8.36 - $23.81 $515,653 - $1.47 Million	61,681 New	61,681 $1.26 Million
Q2 2019 Aug 08, 2019	SELL	$12.9 - $20.8 $613,885 - $989,830	-47,588 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$17.7 - $24.93 $3,894 - $5,484	-220 Reduced 0.46%	47,588 $937,000
Q4 2018 Feb 14, 2019	SELL	$19.05 - $36.45 $4,953 - $9,477	-260 Reduced 0.54%	47,808 $1.08 Million
Q3 2018 Nov 13, 2018	BUY	$34.41 - $44.23 $145,313 - $186,783	4,223 Added 9.63%	48,068 $1.79 Million
Q2 2018 Aug 13, 2018	BUY	$39.21 - $50.29 $19,879 - $25,497	507 Added 1.17%	43,845 $1.72 Million
Q1 2018 May 14, 2018	BUY	$41.7 - $64.16 $1.81 Million - $2.78 Million	43,338 New	43,338 $2.13 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $822M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.